Cognition Therapeutics, Inc. (CGTX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Cognition Therapeutics, Inc. (CGTX)
Go deeper and ask any question about CGTX
Company Performance
Current Price
as of Sep 13, 2024$0.60
P/E Ratio
N/A
Market Cap
$24.08M
Description
Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.
Metrics
Overview
- HQPurchase, NY
- SectorHealth Technology
- IndustryBiotechnology
- TickerCGTX
- Price$0.6001-0.58%
Trading Information
- Market Cap$24.08M
- Float84.22%
- Average Daily Volume (1m)422,554
- Average Daily Volume (3m)1,014,203
- EPS-$0.93
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$7.04M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$14.61M
- EV$38.60M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account
Factset